Peficitinib (類風濕性關節炎治療藥) - 2023年前的預測與市場分析
Peficitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 86 Pages
|Peficitinib (類風濕性關節炎治療藥) - 2023年前的預測與市場分析 Peficitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023|
|出版日期: 2014年12月31日||內容資訊: 英文 86 Pages||
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Peficitinib (also known as ASP015K) is a JAK inhibitor in Phase II of development for RA by Astellas. It is expected to be used in patients with moderate to severe RA who have had an inadequate response to MTX and/or one or more biologic agents, such as the anti-TNFs.